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Abstract
Cyclic α-conotoxin Vc1.1 (cVc1.1) is an orally active peptide with analgesic activity in rat models of
neuropathic pain. It has two disulfide bonds, which can have three different connectivities, one of which is
the native and active form. In this study we used computational modeling and nuclear magnetic
resonance to design a disulfide-deleted mutant of cVc1.1, [C2H,C8F]cVc1.1, which has a larger
hydrophobic core than cVc1.1 and, potentially, additional surface salt bridge interactions. The new variant,
hcVc1.1, has similar structure and serum stability to cVc1.1 and is highly stable at a wide range of pH and
temperatures. Remarkably, hcVc1.1 also has similar selectivity to cVc1.1, as it inhibited recombinant
human α9α10 nicotinic acetylcholine receptor-mediated currents with an IC50 of 13 μM and rat N-type
(Cav2.2) and recombinant human Cav2.3 calcium channels via GABAB receptor activation, with an IC50
of ~900 pM. Compared to cVc1.1, the potency of hcVc1.1 is reduced three-fold at both analgesic targets,
whereas previous attempts to replace Vc1.1 disulfide bonds by non-reducible dicarba linkages resulted in
at least 30-fold decreased activity. Because it has only one disulfide bond, hcVc1.1 is not subject to
disulfide bond shuffling and does not form multiple isomers during peptide synthesis.

Disciplines
Medicine and Health Sciences

Publication Details
Yu, R., Seymour, V. A. L., Berecki, G., Jia, X., Akcan, M., Adams, D. J., Kaas, Q. & Craik, D. (2015). Less is
more: design of a highly stable disulfide-deleted mutant of analgesic cyclic α-conotoxin Vc1.1. Scientific
Reports, 5 13264-1 - 13264-11.

Authors
Rilei Yu, Victoria A. L Seymour, Géza Berecki, Xinying Jia, Muharrem Akcan, David J. Adams, Quentin Kaas,
and David J. Craik

This journal article is available at Research Online: https://ro.uow.edu.au/ihmri/582

www.nature.com/scientificreports

OPEN

received: 16 May 2015
accepted: 23 July 2015
Published: 20 August 2015

Less is More: Design of a Highly
Stable Disulfide-Deleted Mutant of
Analgesic Cyclic α-Conotoxin Vc1.1
Rilei Yu1,3, Victoria A. L. Seymour2, Géza Berecki2, Xinying Jia1,4, Muharrem Akcan1,5,
David J. Adams2, Quentin Kaas1 & David J. Craik1
Cyclic α-conotoxin Vc1.1 (cVc1.1) is an orally active peptide with analgesic activity in rat models
of neuropathic pain. It has two disulfide bonds, which can have three different connectivities, one
of which is the native and active form. In this study we used computational modeling and nuclear
magnetic resonance to design a disulfide-deleted mutant of cVc1.1, [C2H,C8F]cVc1.1, which has a
larger hydrophobic core than cVc1.1 and, potentially, additional surface salt bridge interactions.
The new variant, hcVc1.1, has similar structure and serum stability to cVc1.1 and is highly stable at
a wide range of pH and temperatures. Remarkably, hcVc1.1 also has similar selectivity to cVc1.1, as
it inhibited recombinant human α9α10 nicotinic acetylcholine receptor-mediated currents with an
IC50 of 13 μM and rat N-type (Cav2.2) and recombinant human Cav2.3 calcium channels via GABAB
receptor activation, with an IC50 of ~900 pM. Compared to cVc1.1, the potency of hcVc1.1 is reduced
three-fold at both analgesic targets, whereas previous attempts to replace Vc1.1 disulfide bonds by
non-reducible dicarba linkages resulted in at least 30-fold decreased activity. Because it has only one
disulfide bond, hcVc1.1 is not subject to disulfide bond shuffling and does not form multiple isomers
during peptide synthesis.

Conotoxins are disulfide rich peptide toxins produced by marine cone snail belonging to the Conus
genus1–5. α -Conotoxins are a subgroup of conotoxins characterized by their ability to inhibit nicotinic
acetylcholine receptors (nAChRs)4–6. One α -conotoxin identified in the venom of Conus victoriae, Vc1.17,
has attracted considerable interest for its potent analgesic activity in two models of peripheral neuropathy
of the rat sciatic nerve8, and it is currently being developed as a drug for treating neuropathic pain9.
Vc1.1 is a 16-residue peptide, and its three-dimensional structure comprises a small α -helix as well as
four cysteines forming two disulfide bridges and defining two loops10. The molecular target responsible
for the analgesic activity of Vc1.1 has not yet been clearly identified11,12, as it potently inhibits both the
rat α 9α 10 nAChR10,13 and N-type (Cav2.2) and R-type (Cav2.3) calcium channel currents via the GABAB
pathway12,14.
Recently, an orally active cyclic Vc1.1 (cVc1.1, Fig. 1) was engineered by joining the N- and C-termini
of the peptide without affecting the three-dimensional structure or biological activity9. This molecule
was designed because a major obstacle generally impeding the use of bioactive peptides as drugs is their
high susceptibility to enzymatic degradation15,16. One strategy to improve the stability of peptides is to
cyclize their N- and C-termini16–19, and this strategy has been used successfully with several classes of
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Figure 1. Solution structure of cVc1.1 and sequences of cVc1.1 wild-type and variants considered in this
study. cVc1.1 is an engineered peptide in which a cyclizing linker (grey) was added to confer oral activity
to the analgesic peptide Vc1.1. This peptide comprises two disulfide bonds, which are shown in orange.
The substituted positions are shown in bold. The time-averaged backbone root-mean-square deviations
(< rmsd> ) from cVc1.1 NMR solution structure during 30 ns molecular dynamics simulations are indicated
on the right. The conserved positions of the cVc1.1 variants are shown using lighter color fonts to highlight
the substituted positions.

conotoxins9,19,20. cVc1.1 is the first orally active α -conotoxin variant and its potent activity makes it an
attractive candidate for the development of new analgesics9.
The four cysteines in the peptide primary sequence of cVc1.1 can theoretically form three disulfide-bond
isomers, with one of them being active. In general, the formation of multiple isomers complicates synthesis procedures and significantly increases the cost of production of peptides. It has been shown for
other disulfide-rich conotoxins that only selected disulfide bonds are crucial for stability and activity21–25.
Thus, removing one disulfide-bond of cVc1.1 might not affect its conformation and activity, especially
if the cystine is substituted by judiciously chosen amino acids. To test this hypothesis, we used in silico
modeling to design disulfide deleted variants and electrophysiology recording to study the activity of the
resulting lead peptide. The new Vc1.1 analogue, [C2H,C8F]cVc1.1 has similar three-dimensional structure and activity to Vc1.1. However, since it has only one possible disulfide isomer, the cost of peptide
synthesis and purification is reduced compared to the parent peptide. Specifically, crude cVc1.1 folds into
two isomers in a 72:28 ratio9, whereas [C2H,C8F]cVc1.1 forms only one isomer, gaining an immediate
improvement of 28% in folding yield.

Results

Design of cVc1.1 variants. In the first step of the design process, molecular dynamics was used to

determine which disulfide bond might be removed without affecting the stability of cVc1.1 (Fig. 1 and
S1). Molecular dynamics simulations over 30 ns were performed for the two variants that have a pair
of hemi-cystine residues replaced by alanines. The conformation of [C3A,C16A]cVc1.1 deviated from
the NMR solution structure of cVc1.1 over the course of the simulation, with the Cα root-mean-square
deviation (RMSD) between core regions of the mutant peptide and cVc1.1 on average 1.5 Å (range 1.0–
2.0 Å). By contrast, the structure of [C2A,C8A]cVc1.1 was more similar to that of cVc1.1, with the Cα
RMSD being only 1.2 Å (range 0.5–1.5 Å) (Fig. 1). Therefore, the disulfide bond between positions 3 and
16 seems more important for the stability of cVc1.1 than the disulfide bond between positions 2 and 8.
In a second round of in silico design, various types of residues were introduced at positions 2 and 8
to minimize the effect of the disulfide bond deletion on the global conformation of cVc1.1 (Fig. 1). The
simulations suggested that introducing a Phe residue at position 8 and either a His residue or an Ala
residue at position 2 stabilizes the core region of the peptide. The Cα RMSDs of these variants were of
0.8 and 0.7 Å, respectively, which is comparable to the change in Cα RMSDs observed during similar
simulations of cVc1.1 (Fig. 1). The aromatic residue Phe introduced at position 8 stabilized the α -helix
during the simulations by forming a hydrophobic cluster with residues Cys-3, His-12, Ile-15, and Cys16. The final model suggested that a positively charged His residue at position 2 can potentially form a
cation-π interaction with Phe-8 and a charge interaction with Asp-5. Overall, the computational data
suggested that [C2H,C8F]cVc1.1 is as stable as cVc1.1. Since the new peptide contains a more hydrophobic core relative to the parent peptide we coined it hcVc1.1.

NMR solution structure of hcVc1.1.

The three-dimensional solution structure of hcVc1.1 was determined using 22 dihedral angles and 135 distance restraints, including 54 sequential, 56 medium and
25 long range NOEs. The backbone amide hydrogens of residues Asp-5, Phe-8, Tyr-10, Asp-11, His-12
and Ile-15 appear to be involved in hydrogen bond interactions, as judged by a hydrogen-deuterium
exchange experiment monitored by NMR spectroscopy. The 20 lowest energy models of hcVc1.1 are
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Figure 2. Comparison of the NMR solution structures of hcVc1.1 (pink and gray) and cVc1.1 (blue). (a)
superimposition of the 20 minimum energy NMR models of hcVc1.1 and of the first NMR model of cVc1.1;
the first lowest energy model of hcVc1.1 is in pink and the trace of the other models are in gray; the cVc1.1
lowest energy model is in blue. (b) Hα chemical shifts of hcVc1.1 and cVc1.1.

shown in Fig. 2a. The backbone conformation of the peptide segment 3–16, which corresponds to Vc1.1,
is well-defined, with a maximum Cα RMSD of 0.3 Å between NMR models, whereas the linker region
of the peptide is more flexible.
A comparison of Hα chemical shifts of hcVc1.1 and cVc1.1, shown in Fig. 2b, indicates that the two
peptides adopt very similar globular conformations. The chemical shift deviation of 0.3 ppm observed at
position 3 probably originates from the shielding effect of the aromatic ring current of Phe-826. The Hα
of Cys-3 is indeed ideally located to be shielded as it is in the same plane as the Phe-8 side chain and is
4.5 Å from the center of the phenyl ring (Fig. 2). The iso-shielding lines described by Johnson and Bovey
predict a shift of 0.3 ppm downfield of this proton26, in excellent agreement with the measured difference
between cVc1.1 and hcVc1.1. The backbone conformation of the hcVc1.1 NMR model is similar to that
of cVc1.1 (Fig. 2a), with the core region of the peptide superimposing with a backbone RMSD of 0.8 Å.
The protection of amide protons from solvent can be assessed with amide temperature coefficients
(Δ δ HN/Δ T), and this in turn provides information about the internal hydrogen bond network27. A
comparison of Δ δ HN/Δ T values between hcVc1,1, Vc1.1 and cVc1.1, shown in Fig. 3a, suggests that
the internal hydrogen bond network of hcVc1.1 is slightly better defined than those of the two other
peptides. Indeed, the Δ δ HN/Δ T values for residues between positions 3 and 15 (except for positions 9
and 11) of hcVc1.1 are above -3 ppm/K and are more positive than those of Vc1.1 and cVc1.19,10. Notably,
the hydrogen bonds established by the backbone of modified position 8 are also more stable.

Chaotropic and enzymatic stability of hcVc1.1. The stability of hcVc1.1 over a range of temperatures and pH values was monitored by NMR spectroscopy. Spectra used for solution structure determination of hcVc1.1 were recorded at 280 K at pH 4.5. The Hα chemical shift remained the same for all
temperatures from 280 K to 310 K and for all pH values from 3.1 to 6.0 (Fig. S3). At pH values above 6.5,
the peaks of some residues start to disappear because of fast amide proton exchange with the solvent. The
Scientific Reports | 5:13264 | DOI: 10.1038/srep13264
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Figure 3. (a) Comparison of the amide temperature coefficients of the backbone amid hydrogens of Vc1.1,
cVc1.1 and hcVc1.1 (values are in Table S3). (b) Serum stability of Vc1.1 and hVc1.1 measured as percentage
of peptide remaining in serum. The drop of Vc1.1 remaining at t =  0 is due to disulfide shuffling to an
alternative disulfide isomer9.

Figure 4. Activity of hcVc1.1 at the α9α10 nAChR (a,b). (a) Superimposed representative traces of ACh
(10 μ M)-evoked inward currents obtained in the absence (control) and presence of 1 μ M Vc1.1, cVc1.1 and
hcVc1.1 applied to hα 9α 10 nAChRs expressed in oocytes. (b) Concentration-response curves for inhibition
of hα 9α 10 currents by Vc1.1, cVc1.1 and hcVc1.1. Data points represent relative peak current amplitudes
(I/Icontrol), mean ±  SEM; n =  3–7. IC50 values obtained for Vc1.1, cVc1.1 and hcVc1.1 are 320 nM, 6 μ M and
13 μ M, respectively.

insensitivity of the Hα chemical shifts to pH and temperature changes suggests that the peptide fold is
maintained at physiological temperature and pH conditions.
In human serum, hcVc1.1 was significantly more stable than Vc1.1 (Fig. 3b). After 24 h, about 90%
of the initial peptide remains for hcVc1.1, which is similar to the stability of cVc1.19. Therefore, hcVc1.1
is stable and resistant to enzymatic degradation at physiological conditions, i.e. at pH 7.0 and 310 K.

hcVc1.1 inhibition of recombinant human α9α10 nAChRs in Xenopus oocytes. We previously reported that Vc1.1 and cVc1.1 inhibit rat α 9α 10 nAChRs in a concentration-dependent manner
with IC50 values of 64 nM and 765 nM, respectively9,12. In the present study, Vc1.1, cVc1.1 and hcVc1.1
were examined at human α 9α 10 nAChRs expressed in Xenopus oocytes. The differential effect of 1 μ M
Vc1.1, cVc1.1 or hcVc1.1 on inhibition of the ACh (10 μ M)-evoked current amplitude is shown in Fig 4a.
ACh-evoked current amplitude was inhibited in a concentration-dependent manner by Vc1.1, cVc1.1 or
Scientific Reports | 5:13264 | DOI: 10.1038/srep13264
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Figure 5. Conformations of the interactions between hcVc1.1 (top left) or cVc1.1 (top right) and
hα9α10 nAChR during after 20 ns molecular dynamic simulations. The evolution of the buried surface
area (Surface area) is shown in the bottom graph over the simulation.

hcVc1.1 with the corresponding concentration-response curves giving IC50 values of 320 nM, 6 μ M and
13 μ M (n =  3–7), respectively (Fig. 4b). The potency of Vc1.1 and cVc1.1 at human α 9α 10 nAChRs was
reduced 5- to 8-fold compared to inhibition of rat α 9α 10 nAChRs, potentially reflecting differences in
the α 9 extracellular domain28. α -Conotoxin RgIA is 300-fold less potent on the human versus rat α 9α 10
receptor, and mutational studies indicated that the primary determinant of this disparity is a single
amino acid difference between the rat and human α 9 nAChR subunit at position 5929. In a previous
study30, we suggested that position 59 was also key to the difference in activity of Vc1.1 at inhibiting
rat and human α 9α 10 nAChR, and we suggested that the C-terminal amide of Vc1.1 makes a hydrogen bond with the side chain of rat α 9 Thr-59 but not with human α 9 Ile-59. A molecular dynamics
simulation of the interactions between hcVc1.1 or cVc1.1 and human α 9α 10 (Fig. 5) carried out in the
present study suggests that the higher activity of cVc1.1 compared to hcVc1.1 originates from a better
complementarity at the interface, with an interface area of 1,264 ±  15 Å2 or 1,090 ±  13 Å2, respectively.
By comparison, protease inhibitors have on average an interface area of 1,500 Å2 31, and α -conotoxin ImI
buries 1,600 Å2 surface area at the interface with α 7 nAChR32. The lower interface area of cVc1.1 and
hcVc1.1 seems therefore to correlate with their micromolar range activity.

hcVc1.1 inhibition of human Cav2.3 channels and rat N-type (Cav2.2) channels via GABAB
receptor activation. We recently demonstrated that cVc1.1 potently inhibits N-type (Cav2.2) cal-

cium channels in rat dorsal root ganglion (DRG) neurons and recombinant human Cav2.3 channels
expressed in human embryonic kidney (HEK-293) cells9,33. We have also shown that Vc1.1 inhibition in
these cells is mediated via pertussis toxin-sensitive G protein-coupled GABAB receptor signaling and is
dependent on specific c-Src phosphorylation14,33. Here we show that hcVc1.1 also potently inhibits Ba2+
current through N-type (Cav2.2) calcium channels in rat DRG neurons and recombinant human Cav2.3
calcium channels co-expressed with human GABAB receptors in HEK-293 cells (Fig. S4). We determined
Scientific Reports | 5:13264 | DOI: 10.1038/srep13264
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Figure 6. Concentration-response curves for inhibition by hcVc1.1 of rat N(rN)-type (Cav2.2) channels
in DRG neurons and recombinant human Cav2.3 (hCav2.3) channels co-expressed with human GABAB
receptors in HEK-293 cells. Barium ions at 2 mM and 10 mM were used as charge carrier (IBa) for
experiments with DRG neurons and hCav2.3, respectively. Baclofen (50 μ M) was applied to determine the
baclofen-sensitive IBa fraction. Data points representing mean ±  SEM of peak IBa amplitude (n =  5–8 cells per
data point) were plotted relative to the baclofen-sensitive IBa fraction (see Methods). The best fits with the
Hill equation resulted in IC50 values of 857 ±  516 pM and 961 ±  254 pM for Cav2.2 and hCav2.3, respectively.

IC50 (nM)
Peptide

rN-type (Cav2.2)

hCav2.3

hα9α10 nAChR

Vc1.1

1.7a

ND

320d

cVc1.1

0.3

b

0.29

6,000d

hcVc1.1

0.86

d

0.96

13,000d

c
c

Table 1. IC50 values of synthetic α-conotoxins Vc1.1, cVc1.1 and hcVc1.1 for inhibition of rat DRG
neuron N-type (Cav2.2) channels, human Cav2.3 and human α9α10 nAChRs. Table shows mean values.
ND, not determined. Superscript letters refer to references as follows. aCallaghan et al., 200814. bBerecki
et al., 201433. cClark et al., 20109. dThis study.

the hcVc1.1 concentration dependence of IBa inhibition for N-type (Cav2.2) and Cav2.3 channels (Fig. 6)
and included the half-maximal inhibition concentration (IC50) values in Table 1.
These data demonstrate that hcVc1.1 inhibits human recombinant α 9α 10 nicotinic acetylcholine
receptor (nAChR) currents with a two-fold lower potency than cVc1.1. In rat DRG neurons and HEK cells,
hcVc1.1 had three-fold lower potency than cVc1.1, and inhibited Ba2+ currents through native N-type
(Cav2.2) calcium channels and recombinant human Cav2.3 calcium channels, respectively (Table 1).

Discussion

In this study we simplified the structure of cVc1.1 by removing one of its disulfide bonds while preserving its conformation, stability and selectivity. This new peptide was rationally designed in two steps: in
the first step, a disulfide bond that could be deleted and yet cause minimal perturbation of the scaffold
was identified. The largest loop of [C3A,C16A]cVc1.1 contains three more residues than the largest loop
of [C2A,C8A]cVc1.1, and this size difference provides a simple explanation for the greater flexibility
observed in molecular dynamics simulations of the cystine 3–16 substituted variant. In a second step,
the nature of the amino acids used to substitute the cystine was optimized to increase stability. Our strategy consisted of extending the hydrophobic core, which is identified as an important stabilizing factor
of mini-proteins34,35, and creating additional surface salt bridge interactions, which can in some cases
stabilize proteins but in other cases can either have minimal or detrimental effects on stability36. The
surface charged residues of hcVc1.1, i.e. His-2, Asp-5, Arg-7, Asp-11, His-12, and Glu-14, form a series of
interconnected salt bridges. The theoretical pKa of His-2 side chain is predicted to be 6.5, consistent with
a mainly charged side chain at neutral pH. In summary, the strategy to increase the stability of hcVc1.1
consisted of increasing the hydrophobic/hydrophilic differences between the core and surface positions.
Additionally, the charged side chain of His-2 can also potentially establish a cation-π interaction with
Phe-8, and this type of interaction was shown to have an energy of 2–5 kcal/mol37.
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Remarkably, the disulfide-deleted hcVc1.1 has similar stability to the parent peptide at all tested
temperatures and pH conditions as well as in human serum. This high stability is noteworthy because
disulfide bonds are generally regarded as important for the stability of conotoxins38. A strategy consisting
of creating a compact hydrophobic core was also employed to design the smallest peptide that can adopt
a defined fold without disulfide bond, namely Trp-cage35. One possible advantage of stabilizing a peptide
without using multiple disulfide bonds is to withstand harsher pH conditions and to easily refold upon
mild denaturation. Shuffling of disulfides can indeed result in peptide degradation and significant loss
of activity38. By contrast, hydrophobic cores are not easily disrupted by pH changes and peptides with
small compact hydrophobic cores potentially have better stability in vivo than disulfide stabilized ones if
they can resist enzymatic degradation.
The ability of hcVc1.1 to inhibit currents through human α 9α 10 nAChRs, rat N-type (Cav2.2) and
human Cav2.3 channels is only slightly lower than that of cVc1.1. This result is in stark contrast with
other attempts to modify the nature of Vc1.1 disulfide bonds by replacing them with dicarba bridges,
resulting in ~30–100-fold decrease or loss of activity39. Interestingly, the solution structures of some
dicarba analogues display nearly identical backbone conformations to cVc1.1, suggesting that the drop
in activity is due to subtle modifications of the epitope presentation. Molecular modeling of the complex
between hcVc1.1 and α 9α 10 nAChR suggests that hcVc1.1 and cVc1.1 have shape complementarity at
the interface, which is remarkable because the 2–8 disulfide bond establishes extensive interactions at
the interface. By contrast, the simulations of the interactions of Vc1.1 2–8 dicarba analogue with α 9α 10
nAChR suggested a possible loss of interaction39. The molecular details of the interaction between cVc1.1
and GABAB is unknown, but the 3–16 disulfide bond rather than the 2–8 disulfide bond was proposed to
be important for activity39, in agreement with hcVc1.1 displaying similar activity on the GABAB pathway
as cVc1.1.
The importance of the two disulfide bonds for activity differs between α -conotoxins. For example,
the first loop40 and disulfide bond41 of α -conotoxin ImI (2–8) and not the second disulfide bond42 was
shown to impact inhibition of nAChR α 741,42, in contrast with our results that show that the first disulfide
bond of cVc1.1 could be modified without dramatically impacting its activity. Both ImI and cVc1.1 have
four residues in their first loop, but their second loops have different lengths, with three and seven residues, respectively. This difference of loop length results in different peptide conformations and therefore
interactions with nAChRs. ImI has a shorter α -helix than cVc1.1 and Vc1.19,10,43, and this helix only
establishes a limited number of interactions with the α 7 nAChR44, resulting in the first loop and disulfide
bond of ImI making most of the contacts with the receptor. By contrast, the α -helices of Vc1.130, cVc1.1
and hcVc1.1 (this study) are more deeply buried at the interface than that of ImI (e.g. Tyr-10 of Vc1.1 is
completely buried but Trp-10 of ImI is partly solvated)44, and this larger number and sequence distribution of interface residues for Vc1.1 and cVc1.1 probably make them more robust to modifications of the
first disulfide bond and loop than ImI.

Conclusion

Backbone cross-links, such as disulfide bonds or dicarba bridges, are widely used strategies to stabilize
engineered peptides. We show here that rationally designed non-covalent interactions can stabilize the
internal hydrogen bond network of a peptide scaffold. Remarkably, we were able to globally preserve the
biological activity of a peptide despite swapping one of its disulfide bonds for residues that increase the
hydrophilic/hydrophobic discrepancy between core and surface positions. Considering the structural
simplicity and conformational stability of this new active peptide, hcVc1.1 is an improved lead molecule
for the development of analgesic compounds for the treatment of neuropathic pain.

Materials and Methods

Computational modeling. The designs of cVc1.1 variants considered in this study are summarized

in Fig. 1. Their structures were modeled by substituting the corresponding residues in cVc1.1 NMR
structure9 using Modeller (version 9v7)45,46. The models and the first NMR structure were minimized
and refined using molecular dynamics simulations (MD) performed with the Amber 10 package and
the ff03 force field47,48. The peptides were solvated in a truncated octahedral TIP3P water box containing ~3,000 water molecules. Sodium ions were added to neutralize the systems. The systems were first
minimized with 3,000 steps of steepest descent and then 3,000 steps of conjugate gradient with the
solute restrained to their position by a harmonic force of 100 kcal/mol·Å2. A second minimization was
then performed but with all position restraints withdrawn. The systems were then gradually heated up
from 50 to 300 K in the NVT ensemble over 100 ps with the solute restrained to their position using a
5 kal/mol·Å2 harmonic force potential. The MD simulations were then carried out in the NPT ensemble,
and the position restraints were gradually removed over 100 ps. The production runs were conducted
over 30 ns simulation time with pressure coupling set at 1 atm and a constant temperature of 300 K.
The MD simulations used a time step of 2 fs and, all bonds involving hydrogen atoms were maintained
to their standard length using the SHAKE algorithm49. The particle-mesh Ewald (PME) method was
used to model long-range electrostatic interactions50. Molecular models of the interactions of Vc1.1 and
hcVc1.1 with human α 9α 10 nAChR ligand binding domains were prepared using an homology approach
described previously30. The models were subjected to 20 ns unrestrained MD simulations using a similar
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protocol described above. MD trajectories were analyzed using VMD51 and molecules were drawn using
PyMol (Schrödinger, LLC). The protonation states of side chains were evaluated using propka 3.152.

Peptide synthesis. hcVc1.1 was assembled manually by solid-phase peptide synthesis using Boc

chemistry (Fig. S5). A Boc-Gly-PAM resin was used with the in situ neutralization/2-(1H-benzot
riazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) activation procedure53. Peptides
were cleaved using hydrogen fluoride (HF), with p-cresol and p-thiocresol as scavengers [9:0.8:0.2 (vol/
vol) HF/p-cresol/p-thiocresol] at 0 °C in an ice-water bath for 1.5 h. After cleavage, the peptides were precipitated with ice-cold ether, filtered, dissolved in 50% buffer A/B (buffer A: H2O/0.05% trifluoroacetic
acid; buffer B: 90% CH3CN/10% H2O/0.045% trifluoroacetic acid), and lyophilized. Crude peptides were
purified by reversed-phase HPLC (RP-HPLC) on a Phenomenex C18 column using a gradient of 0–75%
buffer B in 75 min, with the eluent monitored at 214/280 nm. The same conditions were also used in
the subsequent purification steps. Electrospray-mass spectroscopy was used to confirm the molecular
mass of the linear peptide fractions before being pooled and lyophilized for oxidation. Cysteine residues
were oxidized in one step in 0.1 M NH4HCO3 (pH 8 ~ 8.5) at a peptide concentration of 0.3 mg/ml with
stirring overnight at room temperature. After oxidation, the peptides were purified by RP-HPLC using
a gradient of 0–80% buffer B over 180 min. Analytical RP-HPLC and electrospray-mass spectroscopy
confirmed the purity and molecular mass of the synthesized peptides (Fig. S6 and Table S1).

NMR structure determination. hcVc1.1 NMR data were collected on a Bruker Avance 600 MHz spec-

trometer. The 2D experiments used for structure determination included TOCSY, NOESY, DQF-COSY
and ECOSY in 90% H2O/10% D2O at 280 K, pH 4.5 with a mixing time of 300 ms. Peptide concentration
was 1.7 mM and H chemical shifts were calibrated using DSS for all experiments. A D2O exchange experiment was performed to derive the backbone hydrogen bonds for structure calculation in 100% D2O at
280 K, pH 4.5. Hydrogen-deuterium exchange was monitored using 1D-1H NMR spectra recorded at
15 min, 5 h and 30 h. All NMR spectra were analyzed using CcpNmr54.
For structural model calculations, ϕ dihedral angles were derived from 2D DQF-COSY or 1D 1H
NMR experiments using a strategy described by Clark et al.9. The ϕ angles were − 60° ±  30 for His-2,
Cys-3, Ser-4, Arg-7, Phe-8, Asn-9, Tyr-10, Asp-11, Glu-14, and Ile-15, and − 120° ±  30 for Asp-5 and
His-12. Additionally, the χ 1 angles were 180° ±  30 for Cys-3, Asp-5, Phe-8, and Tyr-10, 60° ±  30 for
Ser-4 and Asp-11, − 60° ±  30 for His-12 and Cys-16, 60° ±  150 for Ile-15 and − 60° ±  30 for His-2. The
ϕ and χ 1 dihedral angles were derived from the DQF-COSY and E-COSY experiments, respectively.
Intra-residue NOE and 3J HN-Hα coupling patterns obtained from ECOSY spectra were used for the
assignment of side chain dihedral angles. Hydrogen bond restraints were derived from D2O exchange
experiments. Initial models of hcVc1.1 were computed using Cyana (version 3.0)55 to derive distance
and dihedral restraints, which were used in a simulated annealing protocol implemented in CNS56 to
generate 50 models in explicit water shells. The 20 structures with the lowest energies were selected as
representatives of the solution structure of the peptide. A summary of the energy and geometry parameters of these models is shown in Table S2. The accuracy of the hcVc1.1 NMR models were evaluated
using Molprobity57, as shown in Table S2.

Temperature coefficients of hcVc1.1. hcVc1.1 was dissolved in 90% H2O/ 10% D2O at pH 4.5. The
temperature was increased from 280 K to 310 K and the amide temperature coefficients were measured
using 2D TOSCY experiments performed on a Bruker Avance 600 MHz spectrometer.
Serum stability assay.

Serum stability assay was performed using male AB human serum
(Sigma-Aldrich), as described previously9. The serum was centrifuged at 15,000 g for 15 min to remove
lipids; then it was incubated for 10 min at 37 °C. Triplicate samples were prepared at a 1:10 dilution of the
peptide:serum with a working peptide concentration of 20 mM. 40 μ L of 20% trifluoroacetic acid (TFA)
was added to precipitate the serum proteins at 4 °C. Samples were centrifuged at 14,000 g for 10 min
before analysis on a 0.3 mL/min Phenomenex C18 column using a linear 1% gradient of 0–50% solvent B.
Triplicate samples of peptide in PBS were also run for each time point as controls. An aliquot of the sample was injected, and the amount of intact peptide remaining was determined by integration at 215 nm.

cRNA preparation. Plasmid DNAs encoding human α 9 and α 10 subunits were linearized with
appropriate restriction enzymes, and cRNA was synthesized in vitro using a T7 in vitro transcription kit
(mMessage mMachine; Ambion, Foster City, CA).
Oocyte preparation and microinjection. Stage V-VI oocytes were obtained from Xenopus laevis,

defolliculated with 1.5 mg/ml collagenase (Type I, Sigma) in OR-2 solution (82.5 mM NaCl, 2 mM KCl,
1 mM MgCl2 and 5 mM HEPES at pH 7.4). Oocytes were injected with 5 ng cRNA for each of the
human α 9 and α 10 subunits using an auto-nanoliter injector (Nanojet II, Drummond Scientific Co.,
Broomall, PA). Oocytes were incubated at 18 °C in sterile ND96 solution (96 mM NaCl, 2 mM KCl,
1 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES at pH 7.4) supplemented with 5% FBS, 50 mg/L gentamycin (Sigma-Aldrich) and 100 μ g/units/ml penicillin-streptomycin (Sigma-Aldrich). Electrophysiological
recordings were carried out 2–6 days after microinjection.
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Dorsal root ganglion (DRG) neuron preparation. Rats were killed by cervical dislocation in accord-

ance with the procedures approved by the Animal Ethics Committee of RMIT University. DRG neurons
were enzymatically dissociated from ganglia of 4–21 day-old Wistar rats as described previously14. The
spinal column was hemi-segmented and the paravertebral thoracic and lumbar ganglia were removed.
Ganglia were rinsed in ice-cold Hanks’ balanced salt solution (HBSS, Life Technologies, Carlsbad, CA,
USA) and incubated in 1.5 mg/ml collagenase (type 2; 340 U/mg) (Worthington Biochemical Corp.,
Lakewood, NJ, USA) in HBSS at 37 °C for 30 min. After incubation, ganglia were rinsed three times
with pre-warmed (37 °C) Dulbecco’s Modified Eagle’s medium (DMEM, Life Technologies) supplemented with 10% fetal calf serum and 1% penicillin/streptomycin, and were triturated with a series
of three fire-polished Pasteur pipettes of decreasing tip diameters. Cells were plated on poly-D-lysine/
laminin-coated 12 mm round coverslips (BD Biosciences, Bedford, MA, USA), incubated at 37 °C in high
relative humidity (95%) and controlled CO2 level (5%), and used within 4–48 h.

Human embryonic kidney (HEK) cell culture and transfections.

HEK-293 cells stably expressing
human Cav2.3c (R-type) channel α 1E-c splice variant (GenBank accession no. L29385), human α 2bδ -1
(GenBank accession no. M76559) and human β 3a (RefSeq accession no. NM_000725) auxiliary subunits,
were cultured as previously described33. The cells were transiently cotransfected with plasmid cDNAs
encoding human γ -aminobutyric acid type B (GABAB) receptors, GABAB R1 (RefSeq accession no.
NM_001470; 3 μ g; OriGene Technologies, Inc.) and GABABR2 (RefSeq accession no. NM_005458; 3 μ g;
OriGene Technologies, Inc.), and enhanced green fluorescent protein (eGFP) reporter gene construct
(1 μ g), using the calcium phosphate precipitation method as described previously33. After transfection,
cells were plated on glass coverslips incubated at 37 °C in high relative humidity (95%), and controlled
CO2 level (5%). Transfection medium was then replaced with culture medium, and cells were incubated
at 30 °C in in high relative humidity (95%) and 5% CO2.

Electrophysiological recordings.

Two-electrode voltage clamp recordings from oocytes were carried out at room temperature using a GeneClamp 500B amplifier (Molecular Devices Corp., Sunnyvale,
CA) at a holding potential − 80 mV. Voltage-recording and current-injecting electrodes were pulled from
borosilicate glass (GC150T-7.5, Harvard Apparatus Ltd., Holliston MA) and had resistances of 0.3–1 MΩ
when filled with 3 M KCl. A continuous push/pull syringe pump perfusion system was used to perfuse
oocytes with ND96 at a rate of 2 ml/min. nAChR–mediated currents were evoked by application of
10 μ M acetylcholine (ACh) at a rate of 2 ml/min via the perfusion system. Washout periods of 180–240 s
between applications of ACh were used. Oocytes were incubated with peptides for 4 minutes before
ACh was co-applied. Solutions of hcVc1.1 and the ACh control contained 0.1% bovine serum albumin.
Peak ACh-evoked current amplitude was recorded before and after peptide incubation using pClamp 9
software (Molecular Devices Corp.).
Membrane currents in rat DRG neurons and HEK-293 cells were recorded using the whole-cell configuration of the patch clamp technique with an Axopatch 700B amplifier (Molecular Devices Corp.,
Sunnyvale, CA). For DRG neurons, the external recording solution contained the following (in mM): 150
tetraethylammonium (TEA)-Cl, 2 BaCl2, 10 D-glucose and 10 HEPES, pH 7.3. Fire-polished recording
electrodes were filled with an internal solution containing (in mM): 140 CsCl, 1 MgCl2, 4 MgATP, 0.1
Na-GTP, 5 1,2-bis(O-aminophenoxy)ethane-N,N,N′ ,N′ -tetraacetic acid tetracesium salt (BAPTA)-Cs4,
and 10 HEPES-CsOH, pH 7.3, and had resistances of 1.5–2.2 MΩ . During recording, DRG neurons
were constantly perfused with external recording using a gravity-fed perfusion system at a flow rate of
~1 ml/min.
HEK 293 cells were superfused with a solution containing (mM): 110 NaCl, 10 BaCl2, 1 MgCl2,
5 CsCl, 30 TEA-Cl, 10 D-glucose, and 10 HEPES, pH 7.4 with TEA-OH, at ~1 ml/min. Fire-polished
recording electrodes with tip resistance values of 2–3 MΩ were filled with an intracellular solution containing (mM): 125 K-gluconate, 2 MgCl2, 5 EGTA, 5 NaCl, 4 MgATP, and 10 HEPES, pH 7.25 with CsOH.
Depolarization-activated Ba2+ currents (IBa) were elicited by 0.1 Hz, 120-ms step depolarizations to 0 mV,
from a holding potential of − 80 mV. Currents were filtered at 3 kHz and sampled at 10 kHz using pClamp
9.2 software in combination with Digidata 1322A (Molecular Devices). Leak and capacitive currents were
subtracted using a − P/4 pulse protocol. Solutions with hcVc1.1 and baclofen were prepared from stock
solutions and applied via perfusion in the bath solution.

Curve fitting and statistical analysis. The concentration-response curves of nAChR–mediated

currents in oocytes were obtained by plotting averaged relative peak current amplitude values (I/Icontrol)
against peptide concentration. The data was fitted by the Hill equation I =  Icontrol{[CTX]n/(IC50n + [CTX]n)},
where Icontrol is the maximum peak current amplitude, [CTX] the conotoxin concentration, n the Hill
coefficient, and IC50 the peptide concentration that inhibits 50 % of the maximum response (n =  3 to 6
for each data point).
In DRG neurons and HEK cells, the baclofen-sensitive fraction of IBa (Ibaclofen-sensitive fraction) was defined
using the total IBa (peak IBa in the absence of a compound, Icontrol) and the baclofen-resistant fraction (peak
IBa in the presence of 50 μ M baclofen, Ibaclofen resistant), as follows, Ibaclofen-sensitive fraction =  1 − Ibaclofen-resistant/
Icontrol. Relative peak IBa amplitude values, I, were obtained by normalizing peak IBa values in the presence
of hcVc1.1 (IhcVc1.1) to the Ibaclofen-sensitive fraction, as follows, I =  IhcVc1.1 – Ibaclofen resistant/Icontrol − Ibaclofen resistant.
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Concentration–response curves were obtained by plotting I values versus hcVc1.1 concentration and
fitting the above Hill equation to resulting data. Data are mean ±  SEM (n, number of experiments).
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